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Ivan Diaz-Padilla8,14 and Ruth Plummer 9
BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia
and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib+ gemcitabine ± cisplatin in patients
with resistant/refractory advanced solid tumours.
METHODS: We evaluated the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib+
gemcitabine ± cisplatin using a standard 3+ 3 dose-escalation design. The starting doses were berzosertib 18mg/m2, gemcitabine
875mg/m2 and cisplatin 60 mg/m2.
RESULTS: Fifty-two patients received berzosertib+ gemcitabine and eight received berzosertib+ gemcitabine+ cisplatin. Four
patients receiving berzosertib+ gemcitabine had a total of seven dose-limiting toxicities (DLTs) and three receiving berzosertib+
gemcitabine+ cisplatin had a total of three DLTs. Berzosertib 210mg/m2 (days 2 and 9)+ gemcitabine 1000mg/m2 (days 1 and 8)
Q3W was established as the recommended Phase 2 dose (RP2D); no RP2D was determined for berzosertib+ gemcitabine+
cisplatin. Neither gemcitabine nor cisplatin affected berzosertib PK. Most patients in both arms achieved a best response of either
partial response or stable disease.
CONCLUSIONS: Berzosertib+ gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary
efficacy signs.
CLINICAL TRIAL IDENTIFIER: NCT02157792.
British Journal of Cancer https://doi.org/10.1038/s41416-021-01405-x
BACKGROUND
Chemotherapy drugs, such as platinum agents and gemcitabine,
which induce potentially lethal DNA damage in cancer cells,1 are
part of standard therapies for many cancers.2–6 Resistance to
chemotherapy results in poor clinical outcomes. One mechanism
implicated in both inherent and acquired resistance is the efficient
repair of DNA damage in cancer cells through the activation of the
complex DNA damage response (DDR).7–9
Apical regulators of DDR are ataxia–telangiectasia-mutated
kinase (ATM) and ataxia telangiectasia and Rad3-related protein
kinase (ATR), with ATR responding to exposed single-stranded
DNA that often arises through DNA damage and replication stress,
whereas ATM responds to DNA double-strand breaks. In preclinical
studies, loss of ATM signalling (e.g., through ATM or p53
deficiency, or tumour protein [TP53] mutation) has been reported
to drive reliance on ATR in response to DNA damage;7,10–12
subsequent loss of ATR signalling has been shown to result in
synthetic lethality.7 ATR inhibition is an attractive therapeutic
target for cancers in which DNA-damaging chemotherapy is
utilised as standard therapy, but which retains a substantial unmet
need.13
Berzosertib (formerly M6620, VX-970) is an intravenous (i.v.),
highly potent and selective, first-in-class inhibitor of ATR (IC50=
19 nM).14,15 Preclinical studies have demonstrated antitumour
activity15,16 in synergy with chemotherapy, sensitising lung cancer
cells to DNA-damaging agents, with the greatest effects observed
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with gemcitabine and cisplatin.15 In patient-derived lung tumour
xenografts, berzosertib inhibited ATR activity and enhanced the
efficacy of cisplatin, resulting in inhibition of tumour growth,
including in tumours refractory to cisplatin monotherapy.15
Detailed in vitro and in vivo preclinical studies demonstrated that
ATR inhibition was most effective when administered transiently,
shortly after treatment with DNA-damaging chemotherapy. In
mouse xenografts, a single berzosertib dose administered 12–24 h
after chemotherapy was reported to be optimal and was superior
to simultaneous administration.17
The purpose of this first-in-human, open-label, Phase 1 trial
(ClinicalTrials.gov, identifier: NCT02157792) was to evaluate the
safety, tolerability, pharmacokinetics (PK) and preliminary anti-
tumour activity of berzosertib in combination with gemcitabine,
with or without cisplatin.
METHODS
Study design and treatment
This trial was part of a multicentre, open-label, non-randomised,
Phase 1 study separated into six parts (A, B, B2, C1, C2 and C3). The
focus of this paper is study part A: berzosertib in combination with
gemcitabine with or without cisplatin in patients with advanced
solid tumours; the other parts will be reported elsewhere. Part A
was a 3+ 3 dose-escalation Phase 1 study evaluating the safety,
tolerability, pharmacokinetics (PK) and preliminary efficacy of
berzosertib in combination with gemcitabine with or without
cisplatin (NCT02157792) (Fig. 1). Patients were enrolled in cohorts
of three, with subsequent cohort expansion and dose-escalation
decisions based on safety review, available PK data and
observations of dose-limiting toxicities (DLTs) until the end of
treatment cycle 1.
A 7–14-day lead-in period with single ascending doses of
intravenous (i.v.) berzosertib was planned to assess the safety of
berzosertib monotherapy; the requirement for the lead-in period
was removed after review of safety data both during the study
and from a concurrent study of berzosertib monotherapy.17 A 21-
day chemotherapy dosing cycle was used for berzosertib+
gemcitabine with or without cisplatin treatment. Based on
preclinical studies, a starting dose of 18 mg/m2 and a dosing
regimen of i.v. berzosertib on days 2 and 9, ~24 ± 4 h after dosing
with gemcitabine ± cisplatin, was selected.17 For safety reasons, at
study initiation and during the initial berzosertib dose-escalation
phase, lower starting doses of gemcitabine (875 mg/m2) and
cisplatin (60 mg/m2) were chosen than routinely used in the
clinic.18,19 Patients received i.v. gemcitabine on days 1 and 8, with or
without i.v. cisplatin on day 1. In the berzosertib+ gemcitabine+
cisplatin cohorts, the starting dose of berzosertib did not exceed the
highest dose of berzosertib utilised in the berzosertib+ gemcita-
bine cohorts.
The berzosertib dose was escalated, while the dose of
chemotherapy was kept constant until the berzosertib maximum
tolerated dose (MTD) in combination with gemcitabine (875mg/
m2) ± cisplatin (60 mg/m2) was reached. The MTD was defined as
the highest dose of berzosertib tolerated in combination with a
cisplatin dose between 60 and 75mg/m2 ± a gemcitabine dose
between 500 and 1250mg/m2, inclusive. At this point, doses of
gemcitabine could be increased up to 1250mg/m2 and cisplatin
up to 75mg/m2 in additional cohorts. In the presence of DLTs, the
protocol allowed for reduction in gemcitabine and/or cisplatin
dose to enable escalation of berzosertib in additional cohorts.
Patients received treatment until progressive disease, unaccep-
table toxicity or withdrawal of consent.
Patients
Eligible patients were ≥18 years of age with histologically or
cytologically confirmed metastatic or unresectable solid tumours
and measurable disease according to Response Evaluation Criteria
in Solid Tumours (RECIST) version 1.1,20 for which standard
curative or palliative therapy did not exist or was no longer
effective at the time of study enrolment, or for whom treatment
regimens containing gemcitabine and cisplatin might be con-
sidered. Patients for whom gemcitabine and/or cisplatin were
appropriate treatment options were informed that, given the
exploratory nature of this study, the doses of chemotherapy
would be lower than those given in standard regimens, but were
deemed clinically justified when administered in combination
with berzosertib. Eligible patients had a World Health Organization
performance status of 0–1, adequate bone marrow, liver and
kidney function and a life expectancy of at least 12 weeks. In
addition, patients were required to have received ≤6 cycles of
prior chemotherapy with cisplatin and/or carboplatin (unless
approved by the sponsor medical monitor).
Key exclusion criteria included radiotherapy (except palliative),
endocrine therapy, immunotherapy or chemotherapy within the
4 weeks prior to receiving study therapy, more than six cycles of
prior treatment with cisplatin, ongoing toxicity or recent major
surgery (≤2 weeks of the first dose of study drug), active central
nervous system disease or symptoms within 4 weeks prior to
treatment, cardiac conditions within 6 months prior to treatment,
prior bone marrow transplant or radiation to >15% of bone
marrow and receiving medications that are known to be strong
Part A: berzosertib + gemcitabine ± cisplatin
Screening
• Patients with advanced
  solid tumours
• Aged ≥18 years
• Measurable disease by
  RECIST v1.1
• Lead-in safety phase: berzosertib monotherapy
• Dose escalation: 3 + 3 cohorts
• Part A1: gemcitabine (days 1, 8) + berzosertib (days 2, 9) Q3W
• Part A2: gemcitabine (days 1, 8) + cisplatin (day 1) + berzosertib (days 2, 9) Q3W
 Part B: berzosertib + cisplatin
• Lead-in safety phase: berzosertib monotherapy
• Dose escalation: 3 + 3 cohorts
• Cisplatin (day 1) + berzosertib (days 2, 9) Q3W
RP2D
RP2D
Part B2: berzosertib + irinotecan
• Dose escalation: 3 + 3 cohorts
• Berzosertib (days 1, 15) + irinotecan (days 1, 15) for up to 28-day cycles
Part C: expansion cohort
Part C1
• Advanced NSCLC with TP53 mutation, 
  and/or loss of ATM expression, or neither
• Gemcitabine (days 1, 8) + berzosertib 
  (days 2, 9) Q3W
Part C3
• Platinum-resistant advanced SCLC
• Cisplatin or carboplatin (day 1) 
  + berzosertib (days 2, 9) Q3W
Part C2
• Advanced TNBC with basaloid subtype, 
 BRCA1/2 germline WT
• Cisplatin (day 1) + berzosertib 
  (days 2, 9) Q3W
Fig. 1 Study design (Part A reported here). ATM ataxia–telangiectasia-mutated kinase, DLX dose level X, NSCLC non-small-cell lung cancer,
Q3W every 3 weeks, RECIST response evaluation criteria in solid tumours, SCLC small-cell lung cancer, TNBC triple-negative breast cancer, WT
wild type.
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inhibitors or inducers of CYP3A4 that could not be discontinued at
least one week before the start of treatment and for the duration
of the study.
Full inclusion and exclusion criteria are shown in the Supple-
mentary Information.
Study assessments and endpoints
The primary objective of the study was to assess the safety and
tolerability of multiple ascending doses of i.v. berzosertib, in
combination with gemcitabine with or without cisplatin, in
patients with advanced solid tumours. The secondary objectives
were to determine the MTD, PK and preliminary antitumour
activity of berzosertib in combination with cisplatin. Safety
endpoints assessed were treatment-emergent AEs, the incidence
of DLTs, clinical laboratory values, electrocardiogram outcomes
and vital signs. Secondary endpoints were the MTD of berzosertib
in combination with gemcitabine 500–1250mg/m2 with or
without cisplatin 60–75mg/m2, PK parameters of berzosertib
and the response of advanced solid tumours to berzosertib in
combination with gemcitabine with or without cisplatin.
Treatment-emergent adverse events (TEAEs) and DLTs were
reported using National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 4.0. The DLT
assessment period was limited to cycle 1. All AEs of any grade
were recorded and followed up until resolution. Safety was
evaluated throughout treatment and was used to inform dose-
escalation decisions. Dose-limiting toxicities (DLTs) were generally
defined as any grade ≥3 haematologic or organ toxicity and any
cardiac abnormality. Patients were eligible for DLT analysis if they
either had a DLT before day 21 in cycle 1 or received all doses of
berzosertib and gemcitabine with or without cisplatin in cycle 1
(see Supplementary Information for full definitions of DLTs).
PK assessments for berzosertib were conducted during the
monotherapy lead-in and during cycles 1 and 2. Blood samples for
berzosertib plasma PK assessments were collected following the
single-agent dose, from day 1 of combination dosing (pre-dose,
0.5 h before the end of infusion, at end of infusion and 0.5, 1, 2, 3,
7, 23, 47 and 71 h after the end of infusion), on day 9 (pre-dose)
and cycle 2 day 2 (pre-dose and 2 h after the end of infusion).
Cumulative urine samples were collected for PK assessments on
days 2 and 3 of cycle 1 (pre-dose—3, 3–7, 7–11 and 11–23 h).
Berzosertib concentrations were quantified using a validated
liquid chromatography tandem-mass spectrometry method and
plasma PK was characterised by non-compartmental analyses
using Phoenix WinNonlin 6.4 (Certara USA Inc, Princeton, NJ, USA).
Tumour responses were assessed every two cycles, using
computed tomography, magnetic resonance imaging or bone
scans as deemed appropriate by the investigators, until progres-
sion of disease; responses were assessed by the investigator
according to RECIST version 1.1.
Statistical analysis
Planned enrolment was ~60 patients. Sample size and power was
based on a standard 3+ 3 dose-escalation rule using a binomial
model. The maximally tolerated probability of toxicity associated
with the dose selected by the standard 3+ 3 dose-escalation rule
was calculated to range from ~17 to 26%, with an upper bound
of 33%.
Safety data, baseline patient demographics and disease
characteristics were summarised descriptively for the combina-
tion safety set—which included all enrolled patients who
received at least one dose of study drug. PK data were collected
in the PK analysis set, defined as all enrolled patients who
received at least one dose of berzosertib and provided at least
one measurable post-dose sample. Efficacy analyses were
performed for the full analysis set, which included all enrolled
patients who had a baseline scan, received one or more doses
of study drug and had one or more post-baseline disease
assessments. Standard non-compartmental methods were used
to determine PK parameters.
RESULTS
Patient demographics and disposition
Between December 2012 and June 2017, 60 patients were
enrolled across five sites in the UK and USA. Patient demographics
and disease characteristics are shown in Table 1. Few patients in
the berzosertib+ gemcitabine cohorts (four (8%)) and none in the
berzosertib+ gemcitabine+ cisplatin cohorts had previously
received gemcitabine. Similarly, few patients had a history of
prior treatment with cisplatin (berzosertib+ gemcitabine: ten
(20%), berzosertib+ gemcitabine+ cisplatin: two (25%), Table 2).
Patient disposition for the combination treatment period for
berzosertib+ gemcitabine with or without cisplatin is shown in
Fig. 2. A total of 52 patients were enrolled over ten dose cohorts of
berzosertib+ gemcitabine, and 8 patients were enrolled across two
dose cohorts of berzosertib+ gemcitabine+ cisplatin. The majority
of patients discontinued study treatments due to progressive







(all doses), n= 8
Sex, n (%)
Male 28 (56.0) 4 (50.0)
Female 22 (44.0) 4 (50.0)
Race, n (%)
White 49 (98.0) 8 (100.0)
Asian 1 (2.0) 0
Median (range)
age, years
62 (28–79) 52 (26–71)
Age category, n (%)
<65 years 33 (66.0) 6 (75.0)
≥65 years 17 (34.0) 2 (25.0)
Primary tumour, n (%)
NSCLC 6 (12.0) 1 (12.5)
Pancreatic cancer 2 (4.0) 0
Breast cancer 4 (8.0) 0
Head and neck cancer 1 (2.0) 0
Colorectal cancer 18 (36.0) 4 (50.0)
Othera 19 (38.0) 3 (37.5)
WHO PS, n (%)
0 15 (30.0) 3 (37.5)
1 35 (70.0) 5 (62.5)
Prior chemotherapy,
n (%)
49 (98.0) 8 (100.0)
Platinum-based
chemotherapy
44 (88.0)b 8 (100.0)c
Non-platinum-based
chemotherapy
49 (98.0)d 8 (100.0)e
WHO PS World Health Organization performance status, NSCLC non-small-
cell lung cancer.
aOther did not include small-cell lung cancer or ovarian cancer.
bTen (20%) patients received prior cisplatin; best response of complete
response (n= 1), partial response (n= 3), stable disease (n= 3), progressive
disease (n= 2) and not available (n= 1).
cTwo (25%) patients received prior cisplatin; best response of stable disease
(n= 2).
dFour (8%) patients previously received gemcitabine; best response to
gemcitabine of partial response (n= 1), stable disease (n= 1), progressive
disease (n= 1) and not available (n= 1).
eNo patients received prior gemcitabine.
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disease (berzosertib+ gemcitabine, 58%; berzosertib+ gemcita-
bine+ cisplatin, 63%).
The median number of treatment cycles of berzosertib during
the berzosertib+ gemcitabine combination period was 4.0 (range:
1–20), and within each cohort, the mean relative dose intensity of
berzosertib was 89.6%. The median duration of treatment (overall)
in the berzosertib+ gemcitabine combination period was
83.0 days (range: 2–430). In patients receiving berzosertib+
gemcitabine+ cisplatin, the median number of treatment cycles
was 5.0 (range: 1–14) for both berzosertib + gemcitabine, and 3.5
for cisplatin (range: 1–7), with a mean relative dose intensity of
berzosertib of 80.92%. The median duration of treatment (overall)
for the berzosertib+ gemcitabine+ cisplatin combination period
was 89.5 days (range: 2–290).
Dose escalation and dose-limiting toxicities
In the berzosertib + gemcitabine cohorts, four (8.9%) patients
had a total of seven DLTs; these were distributed across the
different dosing cohorts as follows: berzosertib 72 mg/m2+
gemcitabine 875 mg/m2= three DLTs in two patients, berzo-
sertib 90 mg/m2+ gemcitabine 500 mg/m2= one DLT in one
patient and berzosertib 140 mg/m2+ gemcitabine 500 mg/m2
= three DLTs in one patient. No DLTs occurred in the lowest
berzosertib dose groups (18–60 mg/m2). Of the three DLTs
occurring in the two patients in the berzosertib 72 mg/m2+
gemcitabine 875 mg/m2 cohort, one patient had two DLTs
(grade 3-increased ALT and grade 3 fatigue) and another patient
had a DLT of grade 4 thrombocytopenia. Given these toxicities,
for the next dose-escalation cohort, berzosertib was increased
to 90 mg/m2 but gemcitabine was decreased to 500 mg/m2. The
Table 2. Overview of TEAEs and TEAEs occurring in >15% of patients
by preferred term (combination safety set).







Any grade Grades 3–4a Any grade Grades
3–4a
TEAEs
AEs 49 (98.0) 38 (76.0) 8 (100.0) 8
(100.0)
Serious AEs 24 (48.0) 13 (26.0) 5 (62.5) 5 (62.5)
Treatment-related AEs
AEs 48 (96.0) 26 (52.0) 8 (100.0) 8
(100.0)
Serious AEs 14 (28.0) 4 (8.0) 4 (50.0) 4 (50.0)
AEs leading to study
drug discontinuation
9 (18.0) 5 (10.0) 1 (12.5) 1 (12.5)
AEs leading to death 1 (2.0)b 0
DLTsc 4 (8.0) 3 (37.5)
TEAEs occurring in
≥15% of patients in
either group
Any grade Any grade
Fatigue 32 (64.0) 8 (100.0)
Nausea 31 (62.0) 7 (87.5)
Anaemia 26 (52.0) 3 (37.5)
ALT increased 25 (50.0) 3 (37.5)
Vomiting 22 (44.0) 3 (37.5)
AST increased 19 (38.0) 3 (37.5)
Pyrexia 18 (36.0) 3 (37.5)
Constipation 16 (32.0) 3 (37.5)
Decreased appetite 16 (32.0) 2 (25.0)
Diarrhoea 15 (30.0) 3 (37.5)
Cough 15 (30.0) 1 (12.5)
Neutropenia 14 (28.0) 5 (62.5)
Headache 13 (26.0) 1 (12.5)




Lethargy 12 (24.0) 3 (37.5)




11 (22.0) 2 (25.0)
Dyspnoea 11 (22.0) 1 (12.5)
Back pain 10 (20.0) 0
Abdominal
pain upper
7 (14.0) 2 (25.0)
Dizziness 6 (12.0) 3 (37.5)
Urinary tract infection 6 (12.0) 3 (37.5)
Oedema peripheral 6 (12.0) 2 (25.0)
Leukopenia 6 (12.0) 2 (25.0)
Stomatitis 6 (12.0) 2 (25.0)
Gamma-glutamyl
transferase increased
4 (8.0) 2 (25.0)
Myalgia 4 (8.0) 2 (25.0)
Abdominal
discomfort
2 (4.0) 2 (25.0)
Table 2. continued







Any grade Grades 3–4a Any grade Grades
3–4a
Grade ≥3 TEAEsd Grade ≥3 Grade ≥3
Neutropenia 8 (16.0) 5 (62.5)
ALT increased 8 (16.0) 1 (12.5)
Fatigue 8 (16.0) 1 (12.5)
Thrombocytopenia 5 (10.0) 3 (37.5)
Anaemia 5 (10.0) 1 (12.5)
AE adverse event, ALT alanine aminotransferase, AST aspartate amino-
transferase, DLT dose-limiting toxicity, TEAE treatment-emergent
adverse event.
aNo grade 5 AEs were observed.
bPatient had a reported serious AE of progression of non-small-cell lung
cancer as the cause of death.
cIn berzosertib+ gemcitabine cohorts, the following DLTs were observed:
increased grade 3 ALT and grade 3 fatigue (one patient; berzosertib 72mg/
m2+ gemcitabine 875 mg/m2), increased grade 3 AST (one patient;
berzosertib 90mg/m2+ gemcitabine 500mg/m2), increased grade 3 ALT,
grade 2 AST, and grade 2 blood alkaline. phosphatase (one patient;
berzosertib 140mg/m2+ gemcitabine 500 mg/m2) and grade 4 thrombo-
cytopenia (one patient; berzosertib 72 mg/m2+ gemcitabine 875 mg/m2).
In berzosertib + gemcitabine + cisplatin cohorts, two patients in the
berzosertib 120mg/m2 cohort had DLTs (grade 4 febrile neutropenia and
neutropenia); a third patient (berzosertib 90 mg/m2) had a DLT of
thrombocytopenia (grade 4). All these patients also received gemcitabine
875mg/m2 and cisplatin 60mg/m2.
dOccurring in ≥10% of patients in the berzosertib+ gemcitabine cohorts
or in more than one patient in the berzosertib+ gemcitabine+ cisplatin
cohorts.
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one patient in this cohort with a DLT experienced grade 3-
increased aspartate aminotransferase (AST). Further dose
escalation to berzosertib 140 mg/m2+ gemcitabine 500 mg/m2
resulted in one patient experiencing three DLTs (grade 3 ALT
increase, grade 2 AST increase and grade 2 blood alkaline
phosphatase increase). None of the liver function test elevations
that were considered to be DLTs, were transient, and based on
review of the available safety data, the DLT definition was
modified to exclude transient grade 3 liver function test
elevations (see Supplementary Information).
Screened and enrolled (n = 52) 
Screened and enrolled and received ≥1 dose of study drug (n = 50) 
Did not receive study drug (n = 2)a
Berzosertib 18 mg/m2 + 
gemcitabine 875 mg/m2
(n = 3)
Berzosertib 36 mg/m2 + 
gemcitabine 875 mg/m2
(n = 3)
Berzosertib 60 mg/m2 + 
gemcitabine 875 mg/m2
(n = 4)
Berzosertib 72 mg/m2 + 
gemcitabine 875 mg/m2
(n = 7)b
Berzosertib 90 mg/m2 + 
gemcitabine 500 mg/m2
(n = 6)
Berzosertib 140 mg/m2 + 
gemcitabine 500 mg/m2 
(n = 8)
Berzosertib 210 mg/m2 + 
gemcitabine 500 mg/m2 
(n = 3)
Berzosertib 210 mg/m2 + 
gemcitabine 750 mg/m2 
(n = 3)
Berzosertib 210 mg/m2 + 
gemcitabine 875 mg/m2
(n = 7)
Berzosertib 210 mg/m2 + 
gemcitabine 1000 mg/m2 
(n = 6)
Screened and enrolled and received ≥1 dose of study drug (n = 8) 
Berzosertib 90 mg/m2 + 
gemcitabine 875 mg/m2 + 
cisplatin 60 mg/m2
(n = 6)
Berzosertib 120 mg/m2 + 
gemcitabine 875 mg/m2 + 
cisplatin 60 mg/m2 
(n = 2)
Discontinued (n = 3) 
Reason for discontinuation: 
Progressive disease n = 2 
Patient refused further dosing 
(not due to AE) n = 1 
Discontinued (n = 4) 
Reason for discontinuation: 
AE n = 1 
Progressive disease n = 3
Discontinued (n = 6) 
Reason for discontinuation: 
AE n = 2 
Progressive disease n = 3 
Other n = 1
Discontinued (n = 3) 
Reason for discontinuation: 
AE n = 1 
Progressive disease n = 1 
Other n = 1
Discontinued (n = 7) 
Reason for discontinuation: 
AE n = 1 
Progressive disease n = 4 
Physician decision n = 1 
Other n = 1
Discontinued (n = 3) 
Reason for discontinuation: 
Progressive disease n = 2 
Physician decision n = 1 
Discontinued (n = 5) 
Reason for discontinuation: 
Progressive disease n = 3 
Physician decision n = 1 
Death n = 1c
Discontinued (n = 8) 
Reason for discontinuation: 
AE n = 2 
Progressive disease n = 4 
Patient refused further dosing 
(not due to AE) n = 2
Discontinued (n = 3) 
Reason for discontinuation: 
Progressive disease n = 3 
Discontinued (n = 6) 
Reason for discontinuation: 
AE n = 1 
Progressive disease n = 3 
Patient refused further dosing 
(not due to AE) n = 1 
Physician decision n = 1
Discontinued (n = 6) 
Reason for discontinuation: 
AE n = 1 
Progressive disease n = 4 
Physician decision n = 1
Discontinued (n = 2) 
Reason for discontinuation: 
Progressive disease n = 1 
Physician decision n = 1
a
b
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Subsequently, the berzosertib dose was increased to
210 mg/m2, initially in combination with gemcitabine
500 mg/m2, and then in three subsequent cohorts with
gemcitabine 750, 875 and 1000 mg/m2. No DLTs were reported
for these dose combinations. Gemcitabine dose escalation was
stopped at 1000 mg/m2 due to emerging cumulative haemato-
logic toxicity in later treatment cycles;21 in the berzosertib
210 mg/m2+ gemcitabine 1000 mg/m2 cohort, five patients
presented with grade 1–2 anaemia, four with neutropenia
(two each with grade 1–2 and grade 3) and three with
thrombocytopenia (one each with grade 1–2, grade 3 and
grade 4). Although the MTD for berzosertib in combination with
gemcitabine was not reached, berzosertib 210 mg/m2 (days 2
and 9)+ gemcitabine 1000 mg/m2 (days 1 and 8) every 3 weeks
(Q3W) was chosen as the RP2D as the combination was well
tolerated prior to the emergence of haematologic toxicity and
the berzosertib dose of 210 mg/m2 exceeded that of the
predicted efficacious dose based on preclinical studies.
In the berzosertib+ gemcitabine+ cisplatin cohorts, three
patients had a total of three DLTs. One patient in the berzosertib
90mg/m2+ gemcitabine 875 mg/m2+ cisplatin 60 mg/m2 cohort
had a DLT of grade 4 thrombocytopenia; berzosertib was then
escalated to 120 mg/m2 with the same doses of gemcitabine and
cisplatin. Two patients in the berzosertib 120mg/m2 cohort had
DLTs, one grade 4 febrile neutropenia and one grade 4
neutropenia; both patients discontinued treatment. Following
the observation of these DLTs, dose escalation was halted and the
RP2D was not established for this combination therapy.
Fig. 2 Patient disposition (all patients set). a Berzosertib + gemcitabine cohorts. b Berzosertib + gemcitabine + cisplatin cohorts. aTwo
patients in the berzosertib+ gemcitabine group (one patient each due to receive berzosertib 210 mg/m2+ gemcitabine 500 mg/m2,
berzosertib 210 mg/m2+ gemcitabine 750 mg/m2) never received study treatment due to renal failure before or on day 1. bTwo patients
in the berzosertib 72 mg/m2+ gemcitabine 875 mg/m2 cohort completed treatment per the protocol version at the time, which limited
treatment to six cycles. A later protocol amendment eliminated the restriction on duration of treatment, and thereafter no patient was
considered to have completed treatment. cThis patient had an AE leading to berzosertib discontinuation, however, the primary reason for
discontinuation was recorded as death by the investigator. Note: intra-patient dose escalation did not occur. For berzosertib in
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Fig. 3 Berzosertib plasma concentration–time profiles (PK analysis set). a Single ascending doses of berzosertib for the lead-in period
(berzosertib monotherapy). b Berzosertib+ gemcitabine and berzosertib+ gemcitabine+ cisplatin cohorts. StD standard deviation.
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Safety
Overall, 58 patients were included in the safety set; a summary of
AEs for berzosertib+ gemcitabine with or without cisplatin is
shown in Table 2; fatigue and nausea were the most commonly
reported TEAEs. Twenty-four patients (48%) who received
berzosertib+ gemcitabine experienced one or more serious AEs
(SAEs), the most common of which was pyrexia, which occurred in
six patients (12%), with all other SAEs occurring in two or fewer
patients. In the berzosertib+ gemcitabine+ cisplatin cohorts,
nine patients (18%) experienced TEAEs resulting in discontinua-
tion—the most common of which was fatigue (6%). Fourteen
patients (28%) experienced treatment-related SAEs, the most
common also being pyrexia (12%).
In patients receiving berzosertib+ gemcitabine, grade ≥3 TEAEs
of neutropenia, increased ALT and fatigue each occurred in eight
patients (16%), with anaemia and thrombocytopenia each
occurring in five patients (10%). The most common grade ≥3
TEAEs experienced by patients receiving berzosertib+ gemcita-
bine+ cisplatin were neutropenia in five patients (63%) and
thrombocytopenia in three patients (38%). There were no deaths
due to AEs in patients receiving berzosertib+ gemcitabine+
cisplatin. A full description of the number of treatment-related AEs
of grade ≥3 by dosing cohort can be found in Supplementary
Table S1.
Finally, there were no clinically meaningful trends attributable
to berzosertib treatment identified from laboratory results (serum
chemistry, haematology or urinalysis), vital signs or ECG
parameters.
Pharmacokinetics
Mean PK profiles for the monotherapy lead-in and combination
with gemcitabine with or without cisplatin are shown in Fig. 3. PK
parameters for berzosertib monotherapy lead-in were determined
for 30 patients across the dose range of 18–210mg/m2 and are
shown in Supplementary Table S2. The plasma PK of berzosertib
was characterised by biphasic decline with a moderate-to-high
clearance, high distribution volume and apparent terminal half-life
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Berzosertib 18 mg/m2 + gem 875 mg/m2
Berzosertib 72 mg/m2 + gem 875 mg/m2
Berzosertib 210 mg/m2 + gem 500 mg/m2
Berzosertib 36 mg/m2 + gem 875 mg/m2
Berzosertib 90 mg/m2 + gem 500 mg/m2
Berzosertib 210 mg/m2 + gem 750 mg/m2
Berzosertib 60 mg/m2 + gem 875 mg/m2
Berzosertib 140 mg/m2 + gem 500 mg/m2
Berzosertib 210 mg/m2 + gem 875 mg/m2
Berzosertib 210 mg/m2 + gem 1,000 mg/m2
Berzosertib 90 mg/m2 + gem 875 mg/m2 + cis 60 mg/m2 Berzosertib 120 mg/m2 + gem 875 mg/m2 + cis 60 mg/m2
a
b
Fig. 4 Tumour response. Maximum percentage change in tumour size from baseline and best overall response is shown for patients (full
analysis set) receiving a berzosertib+ gemcitabine (n= 44) and b berzosertib+ gemcitabine+ cisplatin (n= 7). The dashed line at 20%
represents PD, whereas the dashed line at −30% represents PR. Patients with PR had the following primary tumour types: anon-small-cell lung
cancer; bcarcinoma (unknown primary origin); chead and neck cancer; dBRCA2 mutation-positive breast cancer; ecolorectal cancer. cis cisplatin,
gem gemcitabine, PD progressive disease, PR partial response, SD stable disease.
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proportional from 18 to 210mg/m2. Based on 16 patients for the
combination of berzosertib 210mg/m2 with gemcitabine and
eight patients for the combination of berzosertib 90–120mg/m2
with gemcitabine and cisplatin, berzosertib exposures (maximum
observed concentration (Cmax) and area under the concentration
vs. time curve (AUC0-∞)) were consistent with those for
corresponding doses of berzosertib alone (Supplementary
Table S2). For part A, the mean renal clearance of berzosertib
was 3.6 L/h and the mean percentage of berzosertib excreted in
the urine was 5%.
Efficacy
Of the 48 efficacy-evaluable patients who received berzosertib
+ gemcitabine, 4 (8.3%) patients achieved a best response of
partial response (PR) and 29 (60.4%) patients had stable disease
(SD) as their best response (Fig. 4a). Of the four patients in the
berzosertib+ gemcitabine cohort who achieved a best response
of PR, none had previously received gemcitabine, two had
previously received cisplatin and the duration of response
ranged between 71 and 211 days. One of the above patients,
presenting with oestrogen and progesterone receptor-positive,
HER2-negative, germline BRCA2 mutation-positive metastatic
breast cancer, achieved a confirmed PR after four cycles of
berzosertib 210 mg/m2+ gemcitabine 750 mg/m2. She had
previously experienced disease progression after carboplatin
and PARP inhibitor (olaparib) treatment for metastatic disease.
She completed 14 cycles of berzosertib+ gemcitabine and
discontinued study treatment due to progressive disease.21
Another patient, presenting with non-squamous, non-small-cell
lung cancer (NSCLC, adenocarcinoma), achieved a best response
of PR after 12 cycles of berzosertib 140 mg/m2+ gemcitabine
500 mg/m2; PR was sustained through follow-up week eight.
With prior regimens, which included cisplatin, pemetrexed,
erlotinib and docetaxel, he had only attained the best response
of the stable disease.
In the seven efficacy-evaluable patients who received berzo-
sertib+ gemcitabine+ cisplatin, one (14%) patient achieved a
best response of PR and four (57%) patients had SD as their best
response (Fig. 4b). The patient with a best response of PR had
colorectal cancer and had not been previously treated with either
gemcitabine or cisplatin. The duration of response for this patient
was 94 days, following receipt of berzosertib 90mg/m2+
gemcitabine 875mg/m2+ cisplatin 60 mg/m2.
DISCUSSION
This was a first-in-human study exploring the safety, tolerability
and PK of the first-in-class ATR inhibitor berzosertib in combina-
tion with gemcitabine with or without cisplatin in patients with
advanced solid tumours who were resistant to standard therapy.
The MTD of berzosertib with gemcitabine was not reached
because target engagement was predicted at the highest
berzosertib dose evaluated (210mg/m2) and gemcitabine dose
escalation was stopped due to emerging cumulative haematolo-
gic toxicity. Based on the tolerability of the combination,
berzosertib 210 mg/m2 (days 2 and 9)+ gemcitabine 1000mg/
m2 (days 1 and 8) Q3W was established as the RP2D and was
carried forward to be evaluated in patients with advanced NSCLC
in an expansion arm of this study (part C1). A RP2D was not
determined for berzosertib in combination with gemcitabine and
cisplatin as berzosertib dose escalation was not continued after
two patients experienced DLTs of febrile neutropenia or
neutropenia in the berzosertib 120mg/m2+ gemcitabine 875
mg/m2+ cisplatin 60 mg/m2 cohort.
Based on the safety profile reported, berzosertib was consid-
ered well tolerated only in combination with gemcitabine without
cisplatin, however, all side effects reported were consistent with
those reported for gemcitabine and cisplatin when administered
as a single agent.22 However, the prevalence and/or severity of the
observed AEs necessitated lower doses of gemcitabine or cisplatin
than those administered as part of standard chemotherapy
combination regimens.17,23
The PK of berzosertib when administered ~24 h after
gemcitabine, with or without cisplatin, was not significantly
different than that of berzosertib alone. Accumulation with
weekly administration of berzosertib was not observed. As there
was no reason to expect a PK interaction, the exposure of
gemcitabine, with or without cisplatin, was not assessed in
this study.
A total of five patients achieved PR across both cohorts,
providing preliminary evidence of antitumour activity for the
combination of berzosertib+ gemcitabine with or without cispla-
tin in patients with advanced solid tumours. Further, all five
patients with PR had previously received platinum-based che-
motherapy, with three having received prior cisplatin or carbo-
platin. The response observed in a heavily pre-treated patient with
advanced BRCA2-positive breast cancer who previously pro-
gressed on platinum chemotherapy and olaparib suggests that
berzosertib may have a role in overcoming platinum and/or PARP
inhibitor resistance, as has been demonstrated in preclinical
experiments.24 The expansion cohorts (part C) of this study further
evaluated berzosertib in combination with gemcitabine or
cisplatin/carboplatin in tumour types in which TP53 mutations
and/or ATM deficiency are common, or which are likely to be
under replicative stress—including NSCLC,25 triple-negative breast
cancer26 and small-cell lung cancer27—and may be particularly
susceptible to ATR inhibition.
Recently, berzosertib has been shown to be both well
tolerated and efficacious in combination with gemcitabine in a
Phase 2 randomised study (berzosertib+ gemcitabine vs. gemci-
tabine alone) in platinum-resistant high-grade serous ovarian
cancer (n= 70).28 It has also shown preliminary clinical antitumour
activity in combination with other chemotherapy agents, includ-
ing with topotecan in heavily pre-treated patients with advanced
solid tumours, including durable responses in relapsed platinum-
resistant small-cell lung cancer.23 A proof-of-concept Phase 2 study
with berzosertib in combination with topotecan in patients with
SCLC reported an objective response rate of 36% (9/25), with a
duration of response ≥6 months.29 In a separate Phase 1 dose-
escalation study, berzosertib has also been evaluated in combina-
tion with carboplatin, where it has shown some preliminary signs
of activity in platinum and PARP inhibitor pre-treated patients.17
The combination of carboplatin and berzosertib is now being
compared to carboplatin–docetaxel in men with pre-treated
metastatic castrate-resistant prostate cancer (NCT03517969).
Future work should continue to evaluate potential biomarkers
that may be predictive of response, in order to elucidate
mechanisms of action and identify patients most likely to benefit
from ATR inhibition in combination with chemotherapy.
Other studies of berzosertib are currently investigating patient
populations with advanced solid tumours selected by various
genetic abnormalities, including ATM truncating mutations, germ-
line BRCA mutation and other alterations likely to disrupt
homologous recombination repair or cause replicative stress
(NCT03718091).
In conclusion, this study has demonstrated that berzosertib is
well tolerated in combination with gemcitabine in patients with
advanced solid tumours. Berzosertib has also demonstrated
preliminary clinical activity, building the foundation for subse-
quent Phase 2 studies, where these early signs of clinical activity
have been confirmed.28,29 Further late-stage clinical
evaluation of berzosertib is warranted and the identification of
predictive biomarkers of response is the critical next step in
order for berzosertib to potentially become an additional
therapeutic option in the treatment armamentarium for cancer
patients.
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